IL207378A0 - Pharmaceutical solid state forms - Google Patents

Pharmaceutical solid state forms

Info

Publication number
IL207378A0
IL207378A0 IL207378A IL20737810A IL207378A0 IL 207378 A0 IL207378 A0 IL 207378A0 IL 207378 A IL207378 A IL 207378A IL 20737810 A IL20737810 A IL 20737810A IL 207378 A0 IL207378 A0 IL 207378A0
Authority
IL
Israel
Prior art keywords
solid state
state forms
pharmaceutical solid
pharmaceutical
forms
Prior art date
Application number
IL207378A
Other languages
English (en)
Original Assignee
Harbor Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harbor Biosciences Inc filed Critical Harbor Biosciences Inc
Publication of IL207378A0 publication Critical patent/IL207378A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0033—Androstane derivatives substituted in position 17 alfa and 17 beta
    • C07J1/004—Androstane derivatives substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
    • C07J1/0048—Alkynyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
IL207378A 2008-02-05 2010-08-03 Pharmaceutical solid state forms IL207378A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2647208P 2008-02-05 2008-02-05
US9369408P 2008-09-02 2008-09-02
PCT/US2009/033280 WO2009100258A1 (en) 2008-02-05 2009-02-05 Pharmaceutical solid state forms

Publications (1)

Publication Number Publication Date
IL207378A0 true IL207378A0 (en) 2010-12-30

Family

ID=40952461

Family Applications (1)

Application Number Title Priority Date Filing Date
IL207378A IL207378A0 (en) 2008-02-05 2010-08-03 Pharmaceutical solid state forms

Country Status (10)

Country Link
US (4) US8518922B2 (enExample)
EP (1) EP2249838A4 (enExample)
JP (1) JP2011511011A (enExample)
KR (1) KR20100113602A (enExample)
CN (2) CN101939009B (enExample)
AU (1) AU2009212314C1 (enExample)
CA (1) CA2712005C (enExample)
EA (1) EA018974B9 (enExample)
IL (1) IL207378A0 (enExample)
WO (1) WO2009100258A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2225230T (pt) 2007-12-07 2016-12-07 Vertex Pharma Formas sólidas de ácido 3-(6(1-(2,2-difluorobenzo[d][1,3] dioxol-5-il) ciclopropanocarboxamido)-3-metilpiridin-2-il) benzoico
HUE028337T2 (en) * 2008-04-03 2016-12-28 Neurmedix Inc Shapes of a drug in a solid state
WO2011066582A1 (en) * 2009-11-30 2011-06-03 Harbor Biosciences, Inc. Anticancer compounds and screening method
AU2011205230A1 (en) 2010-01-13 2012-08-02 Caris Life Sciences Switzerland Holdings Gmbh Detection of gastrointestinal disorders
KR20130056855A (ko) 2010-03-01 2013-05-30 카리스 라이프 사이언스 룩셈부르크 홀딩스 치료진단용 생물학적 지표들
KR20130043104A (ko) 2010-04-06 2013-04-29 카리스 라이프 사이언스 룩셈부르크 홀딩스 질병용 순환 생물학적 지표들
US20120220560A1 (en) * 2010-12-17 2012-08-30 White Steven K Steroid tetrol solid state forms
CN104173353B (zh) * 2013-05-22 2018-08-21 中国医药工业研究总院 不含表面活性剂的固体制剂及其制备方法
KR102280372B1 (ko) * 2013-11-12 2021-07-22 버텍스 파마슈티칼스 인코포레이티드 Cftr 매개된 질환 치료용 약제학적 조성물의 제조 방법
CN105434444B (zh) * 2014-09-29 2021-02-05 上海奥奇医药科技有限公司 一种A-失碳-5α雄甾烷化合物的口服制剂
CN113559075A (zh) 2014-11-17 2021-10-29 康泰科思特生物制药公司 奥那司酮延长释放组合物和方法
US10308676B2 (en) 2015-09-25 2019-06-04 Context Biopharma Inc. Methods of making onapristone intermediates
JP2019503353A (ja) 2015-12-15 2019-02-07 コンテキスト・バイオファーマ・インコーポレイテッド 非晶質オナプリストン組成物およびそれを作製する方法
US20180148471A1 (en) 2016-11-30 2018-05-31 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection
CN110446705B (zh) * 2017-03-30 2023-04-14 默克专利股份公司 (s)-[2-氯-4-氟-5-(7-吗啉-4-基喹唑啉-4-基)苯基]-(6-甲氧基-哒嗪-3-基)甲醇的固体形式
RU2668526C1 (ru) * 2017-08-18 2018-10-01 Федеральное государственное бюджетное учреждение "Информационно-методический центр по экспертизе, учету и анализу обращения средств медицинского применения" Федеральной службы по надзору в сфере здравоохранения Способ идентификации и последующего количественного определения основных компонентов в инъекционных лекарственных средствах
WO2020113237A1 (en) 2018-11-30 2020-06-04 Caris Mpi, Inc. Next-generation molecular profiling
CN111773388B (zh) * 2019-04-04 2023-07-18 上海奥奇医药科技有限公司 A-失碳-5α雄甾烷化合物类药物与抗癌药物的联合应用
IL293489A (en) 2019-12-02 2022-08-01 Caris Mpi Inc predictor of pan-cancer platinum response

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE681869C (de) * 1935-11-22 1939-10-03 Schering Ag Verfahren zur Darstellung von tertiaeren Alkoholen der Cyclopentanopolyhydrophenanthrenreihe
CH202847A (de) * 1937-06-26 1939-02-15 Chem Ind Basel Verfahren zur Darstellung von Acetylen-Derivaten der Cyclopentanopolyhydrophenanthren-Reihe.
DK0614456T3 (da) * 1992-08-28 1999-12-06 Bone Care Int Inc 1alfa,24(S)-dihydroxy-vitamin D2, dets fremstilling og anvendelse
US5567830A (en) * 1994-02-14 1996-10-22 Cocensys, Inc. Process for synthesis of acetylenic carbinols
PL189256B1 (pl) 1996-03-29 2005-07-29 Duphar Int Res Związki piperazyny i piperydyny, sposób ich wytwarzania, kompozycja farmaceutyczna zawierająca te związki, zastosowanie tych związków do wytwarzania leków
ZA986614B (en) * 1997-07-25 1999-01-27 Gilead Sciences Nucleotide analog composition
US7045513B1 (en) * 1999-03-18 2006-05-16 Genelabs Technologies, Inc. DHEA composition and method
WO2001023405A2 (en) 1999-09-30 2001-04-05 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment of androgen receptor driven conditions
US6777399B2 (en) * 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
MXPA03005339A (es) * 2000-12-14 2004-03-26 Johnson & Johnson Productos de hormona esteroide que comprenden un agente de estabilizacion en forma no cristalina.
AR034206A1 (es) 2001-02-16 2004-02-04 Solvay Pharm Bv Un procedimiento para la preparacion de mesilatos de derivados de piperazina y dichos mesilatos
DE10314610A1 (de) * 2003-04-01 2004-11-04 Aventis Pharma Deutschland Gmbh Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung
US7540016B2 (en) * 2004-07-21 2009-05-26 Beachhead Solutions, Inc. System and method for lost data destruction of electronic data stored on a portable electronic device which communicates with servers that are inside of and outside of a firewall
US7964604B2 (en) * 2005-02-18 2011-06-21 Solvay Pharmaceuticals B.V. Bifeprunox mesylate maintenance dose compositions and methods for using the same
TW200730505A (en) * 2005-12-07 2007-08-16 Merck & Co Inc Polymorphs of an androgen receptor modulator
TWI305979B (en) * 2006-03-24 2009-02-01 Hon Hai Prec Ind Co Ltd Wireless transceiving system
CN103211821A (zh) * 2006-04-22 2013-07-24 霍利斯—伊登医药公司 药物和用途
DE102007063671A1 (de) * 2007-11-13 2009-06-25 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung

Also Published As

Publication number Publication date
KR20100113602A (ko) 2010-10-21
HK1147695A1 (en) 2011-08-19
WO2009100258A1 (en) 2009-08-13
EA018974B9 (ru) 2014-04-30
CA2712005C (en) 2014-04-15
EA018974B1 (ru) 2013-12-30
US9314471B2 (en) 2016-04-19
CN101939009B (zh) 2013-07-17
US8518922B2 (en) 2013-08-27
JP2011511011A (ja) 2011-04-07
CA2712005A1 (en) 2009-08-13
EP2249838A1 (en) 2010-11-17
AU2009212314C1 (en) 2014-05-08
US20130345455A1 (en) 2013-12-26
US20130345184A1 (en) 2013-12-26
AU2009212314A1 (en) 2009-08-13
CN103467554A (zh) 2013-12-25
AU2009212314B2 (en) 2013-11-21
EP2249838A4 (en) 2012-05-02
US20090291932A1 (en) 2009-11-26
US20130338125A1 (en) 2013-12-19
EA201070713A1 (ru) 2011-08-30
CN101939009A (zh) 2011-01-05

Similar Documents

Publication Publication Date Title
IL237391A0 (en) Pharmaceutical combination
IL207378A0 (en) Pharmaceutical solid state forms
ZA201104336B (en) Pharmaceutical compounds
GB0816372D0 (en) Pharmaceutical compounds
GB0820819D0 (en) Pharmaceutical compounds
GB0801416D0 (en) Pharmaceutical compounds
GB0816371D0 (en) Pharmaceutical compounds
ZA201104348B (en) Pharmaceutical preparation
GB0810615D0 (en) Novel pharmaceutical
GB0812969D0 (en) Pharmaceutical compounds
ZA201102715B (en) Solid pharmaceutical composition
PT2271618E (pt) Compostos farmacêuticos
GB0816370D0 (en) Pharmaceutical compounds
HU0800591D0 (en) Stable pharmaceutical combination
GB0815972D0 (en) Pharmaceutical preparation
EP2268278A4 (en) PHARMACEUTICAL COMPOSITION
IL208953A0 (en) Pharmaceutical combination
GB0810857D0 (en) Pharmaceutical compounds
IL208788A (en) Pharmacy-based formulation
ZA201100871B (en) Solid pharmaceutical composition
GB0810617D0 (en) Novel pharmaceutical
GB0818725D0 (en) Pharmaceutical composition
GB0817969D0 (en) Pharmaceutical composition
HU0800414D0 (en) Pharmaceutical combination
GB0804486D0 (en) Novel pharmaceutical composituons